Skip to main content
Log In
More
Log in via Institution
Log in via OpenAthens
Log in using your username and password
For personal accounts OR managers of institutional accounts
Username
*
Password
*
Forgot your log in details?
Register a new account?
Forgot
your user name or password?
Basket
Search
More
Search for this keyword
Advanced search
Latest content
Browse by collection
Archive
Authors
About
Search for this keyword
Advanced search
Close
More
Main menu
Latest content
Browse by collection
Archive
Authors
About
Log in
More
Log in via Institution
Log in via OpenAthens
Log in using your username and password
For personal accounts OR managers of institutional accounts
Username
*
Password
*
Forgot your log in details?
Register a new account?
Forgot
your user name or password?
BMJ Journals
You are here
Home
Archive
Volume 10, Issue 10
First-in-human phase I/II, open-label study of the anti-OX40 agonist INCAGN01949 in patients with advanced solid tumors
Email alerts
Article metrics
Article menu
Article
Text
Article
info
Citation
Tools
Share
Rapid Responses
Article
metrics
Alerts
PDF
PDF +
Supplementary
Material
Clinical/translational cancer immunotherapy
Original research
First-in-human phase I/II, open-label study of the anti-OX40 agonist INCAGN01949 in patients with advanced solid tumors
Online download statistics by month:
Online download statistics by month: October 2022 to February 2024
Abstract
Full
Pdf
Oct 2022
118
120
14
Nov 2022
693
696
258
Dec 2022
217
219
73
Jan 2023
187
188
65
Feb 2023
223
225
52
Mar 2023
199
203
56
Apr 2023
174
177
61
May 2023
150
150
85
Jun 2023
137
139
43
Jul 2023
165
171
50
Aug 2023
157
158
45
Sep 2023
161
162
57
Oct 2023
166
166
59
Nov 2023
176
178
46
Dec 2023
138
138
59
Jan 2024
101
104
41
Feb 2024
116
118
40
Total
3278
3312
1104
Read the full text or download the PDF:
Subscribe
Log in
Log in via Institution
Log in via OpenAthens
Log in using your username and password
For personal accounts OR managers of institutional accounts
Username
*
Password
*
Forgot your log in details?
Register a new account?
Forgot
your user name or password?